Publication:
How antimalarial drug resistance affects post-treatment prophylaxis

dc.contributor.authorNicholas J. Whiteen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherUniversity of Oxforden_US
dc.date.accessioned2018-07-12T02:31:29Z
dc.date.available2018-07-12T02:31:29Z
dc.date.issued2008-03-07en_US
dc.description.abstractSlowly eliminated antimalarial drugs suppress malaria reinfections for a period of time determined by the dose, the pharmacokinetic properties of the drug, and the susceptibility of the infecting parasites. This effect is called post-treatment prophylaxis (PTP). The clinical benefits of preventing recrudescence (reflecting treatment efficacy) compared with preventing reinfection (reflecting PTP) need further assessment. Antimalarial drug resistance shortens PTP. While blood concentrations are in the terminal elimination phase, the degree of shortening may be estimated from measurements of in-vitro susceptibility and the terminal elimination half-life. More information is needed on PTP following intermittent preventive treatments, and on the relationship between the duration of PTP and immunity, so that policy recommendations can have a firmer evidence base. © 2008 White; licensee BioMed Central Ltd.en_US
dc.identifier.citationMalaria Journal. Vol.7, (2008)en_US
dc.identifier.doi10.1186/1475-2875-7-9en_US
dc.identifier.issn14752875en_US
dc.identifier.other2-s2.0-40149110041en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/19357
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=40149110041&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleHow antimalarial drug resistance affects post-treatment prophylaxisen_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=40149110041&origin=inwarden_US

Files

Collections